$186.46
+2.0%ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Chief Commercial Officer - SaaS
Compensation
$1,230,965
Chief Compliance Officer
Chief Executive Officer & Chairman
Compensation
$2,974,477
Chief Financial Officer
Compensation
$971,973
Chief Information Officer
Chief Investor Relations Officer
Chief Legal Officer & Secretary
Compensation
$889,117
Chief Marketing Officer
Chief People Officer
Chief Product Officer
Compensation
$1,311,404
Founder, Chair Emeritus & Director
Compensation
$459,719
Founder, Chair Emeritus & Non-Executive Director
Compensation
$413,215
During the last 12 months, insiders have sold $30.71M worth of RMD shares, with no buying activity reported.
0
0.00
18.0K
4.09M
-4.1M
-$4.09M
0
0.00
24.1K
6.16M
-6.2M
-$6.16M
0
0.00
37.7K
10.00M
-10.0M
-$10.00M
0
0.00
39.5K
10.47M
-10.5M
-$10.47M
No buying activity
Farrell Michael J.
Director, Officer: Chairman And Ceo
$20.08M
Sandercock Brett
Officer: Chief Financial Officer
$5.44M
Farrell Peter C
Director
$3.71M
Hernandez John
Director
$739K
De Witte Jan
Director
$646K
Strong bearish signal with $30.71M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
RMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | October 02, 2025 | June 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | October 03, 2024 | June 30, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | October 05, 2023 | June 30, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 05, 2022 | October 05, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | October 06, 2021 | October 06, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 06, 2020 | October 06, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | October 08, 2019 | November 21, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | October 03, 2018 | November 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 25, 2017 | November 16, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | September 26, 2016 | November 16, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.